ArticleBMC infectious diseases2025
Serotype distribution and antimicrobial susceptibility patterns of Streptococcus pneumoniae isolates in the post-pneumococcal conjugate vaccine era in Nigeria: a hospital-based cross-sectional study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomic analysis ofMicrobial genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPneumococcal conjugate vaccines (PCV7/10/13) have reduced vaccine-serotype disease and resistance globally, including indirect effects in unvaccinated populations. Nigeria introduced PCV10 in 2016, but its impact on serotype distribution and resistance in Delta State remains poorly defined.
aimTo determine the prevalence of Streptococcus pneumoniae, the circulating serotypes, and their antimicrobial susceptibility patterns among children and adults ~ 3 years post PCV10 introduction in Delta State, Nigeria.
methodsWe processed 622 clinical specimens (July 2019–November 2020) from two hospitals. Isolates with α-hemolysis and optochin susceptibility were confirmed as pneumococci by multiplex PCR targeting cpsA. Serotyping used a multiplex PCR panel covering PCV13 serotypes. Antimicrobial susceptibility testing was by Kirby–Bauer disk diffusion; S/I/R (Susceptibility/Intermediate/Resistance) categories were assigned only for agents with validated disk-diffusion breakpoints in S. pneumoniae (erythromycin, clindamycin, tetracycline, levofloxacin, trimethoprim–sulfamethoxazole). Because neither oxacillin screening nor MIC testing was performed, β-lactams, imipenem, and vancomycin were reported as inhibition-zone diameters without categorical interpretation.
resultsOf 622 specimens, 8 (1.3%) yielded phenotypic pneumococci; 5/8 (62.5%) were cpsA-positive, all from non-invasive specimens. By age, 3/5 (60%) were from adults ≥ 61 years, and 1/5 each from 11 to 20 and 21–40 years. All five isolates were non-vaccine types (non-PCV13); specific serotypes were not resolved. Among drugs with validated disk-diffusion breakpoints, 4/5 (80%) isolates were susceptible to erythromycin, clindamycin, and levofloxacin; all 5/5 (100%) were non-susceptible to trimethoprim–sulfamethoxazole; and 3/5 (60%) were non-susceptible to tetracycline. Using a non-β-lactam definition, multidrug resistance (MDR) was detected in 1/5 (20%) isolates.
conclusionIn this two-site survey, pneumococci were infrequently recovered and comprised non-vaccine types that largely retained susceptibility to macrolide, lincosamide, and fluoroquinolone agents, alongside uniform non-susceptibility to trimethoprim–sulfamethoxazole and sporadic MDR. Although numbers are small, these findings support continued serotype-specific and resistance surveillance incorporating MIC testing and molecular typing to track serotype replacement, clarify resistance mechanisms, and evaluate the longer-term impact of PCV10 in Delta State, Nigeria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.